Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Table 3 Systemic toxicity after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy

Authors, yr	Patients (n)	HIPEC drug schedule	EPIC	Severe hematological toxicity (%)	Renal toxicity (%)	Mortality (%)	Risk factor for systemic toxicity
Jacquet et al[21], 1996	60	MMC	60	7	-	5	Not identified
Schnake et al[44], 1999	242	MMC/CDDP	Yes	2.5	-	4	Not identified
Stephens et al[10], 1999	200	MMC	145	4	-	1.5	Not identified
Glehen et al[11], 2003	216	MMC or CDDP or CDDP + MMC	-	4.6	1.3	3.2	NA
Verwaal et al[22], 2004	102	MMC	-	18.6	4.9	8	NA
Shen et al[35], 2004	77	MMC	-	19	-	4	NA
Smeenk et al[12], 2006	103	MMC	-	10.6	-	11	NA
Elias et al[43], 2005	83	Ox + CPT11 + ev 5-FU + AF	-	48	-	4.8	Duration of proc; PCI
Kusamura et al[42], 2007	247	CDDP + MMC or CDDP + Dx	-	5.3	5.7	1.2	CDDP dose > 240 mg; CDDP + Dx schedule for HIPEC

CHT: Chemotherapy; HIPEC: Hyperthermic intraperitoneal chemotherapy; EPIC: Early postoperative intraperitoneal chemotherapy; MMC: Mitomycin-C; Ox: Oxaliplatin; CDDP: Cisplatin; CPT11: Irinotecan; 5-FU: 5-fluorouracil; Dx: Doxorubicin; PCI: Peritoneal Cancer Index.